Supplementary Information: Accelerating Monoclonal Antibody Quality Control: The Role of LC–MS in Upstream Bioprocessing
This information is supplementary to the article “Accelerating Monoclonal Antibody Quality Control: The Role of LC–MS in Upstream Bioprocessing”, which was published in the May 2025 issue of Current Trends in Mass Spectrometry.
The following document below includes the following supplementary information for the article "Accelerating Monoclonal Antibody Quality Control: The Role of LC–MS in Upstream Bioprocessing”, which was published in the May 2025 issue of Current Trends in Mass Spectrometry.
- Table S1: Applied dilution factors for LC–MS analysis
- Table S2: Eluents used for LC–MS analysis
- Table S3: LC parameters used for sample analysis
- Table S4: LC gradient used for sample analysis
- Table S5: Mass errors for the duplicated LC–MS measurements (deconvoluted spectra) of different glycoforms in the varied cultivation conditions
Understanding FDA Recommendations for N-Nitrosamine Impurity Levels
April 17th 2025We spoke with Josh Hoerner, general manager of Purisys, which specializes in a small volume custom synthesis and specialized controlled substance manufacturing, to gain his perspective on FDA’s recommendations for acceptable intake limits for N-nitrosamine impurities.
